


## Technology Advisory Committee D Interests Register Efgartigimod for treating generalised myasthenia gravis [ID4003] Publication Date: 7 February 2024

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Rachel Elliot	Committee Member	Direct – financial	Rachel received payment by CSL Behring for an advisory board this year on an unrelated topic	03/07/2023	It was agreed that Rachel's declaration would not prevent her from participating in discussions on this appraisal
Ivan Koychev	Committee Member	Direct- Non- financial personal interest	Ivan declared that a close friend of his is Senior Medical Director at Argenx.	16/11/2023 18/07/2023	It was agreed that Ivan's declaration would not prevent him from participating in discussions on this appraisal
Dr Channa Hewamadduma	Clinical Expert	Direct – financial	Dr Hewamadduma declared the following financial interests:  • UCB Pharma Received funding for consultancy on scientific or educational advisory boards	16/11/2023 26/06/2023	It was agreed that Dr Hewamadduma's declarations would not prevent him from providing expert advice to the committee.



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul> <li>Argenx Received funding for consultancy on scientific or educational advisory boards</li> <li>Lupin Received funding for consultancy on scientific or educational advisory boards</li> <li>Roche Received funding for consultancy on scientific or educational advisory boards</li> <li>Biogen Received funding for consultancy on scientific or educational advisory boards</li> <li>Association of British         Neurologists (ABN)- Chaired a symposium organised by Biogen on SMA- new insights from basic science to understand SMA</li> <li>Association of British         Neurologists (ABN) –Lecture on Mechanisms of Myasthenia gravis – in an educational symposium on MG arranged by ARGENX</li> <li>One off Consultation for UCB</li> </ul>		



Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Channa Hewamadduma	Expert	Direct-non financial  Indirect -	Dr Hewamadduma declared his involvement in clinical trials in MG/CIDP: sponsors: UCB, Argenx (ongoing), Jansen (setup)  Dr Hewamadduma also declared the following indirect interests:	26/06/2023	It was agreed that Dr Hewamadduma's declarations would not prevent him from providing expert advice to the committee.
		professional	<ul> <li>Publication- author –         Contributing author to Phase         3 clinical trial and         manuscript. Lancet         Neurology 2023 (May)</li> <li>2023 March: Core teaching         faculty of an Academic         programme on Myasthenia         Gravis at Neurology         Academy- who were         sponsored by ARGENX and         UCB</li> </ul>		
Dr Fiona Norwood	Clinical Expert	Direct – financial and non-financial interests	Dr Norwood declared the following interests:	16/11/2023 12/12/2022	It was agreed that Dr Norwood's declarations would not prevent her from providing expert advice to the committee.